ScripMore than a year after reporting promising early data for its allogeneic chimeric antigen receptor natural killer (CAR-NK) candidate NKX101 in relapsed/refractory acute myeloid leukemia, Nkarta, Inc.
ScripBroader stock market indices continue to swing wildly up and down as new data emerge showing that inflation is easing, but also that other parts of the economy continue to struggle. However, biotechno
Pink SheetBiologic therapies have dominated oncology pipeline news this month, with US submissions from Merck & Co. Inc. , AstraZeneca PLC , Immunomedics Inc. , and Y-mAbs Therapeutics Inc. ; breakthrough d
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Celgene Hopes Exscientia’s P